Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity

BMC Cancer

Volumn 9, Issue , 2009, Pages 272-

  Major, Pierre P ^a   Cook, Richard J ^b   Lipton, Allan ^c   Smith, Matthew R ^d   Terpos, Evangelos ^e   Coleman, Robert E ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

^c PENN STATE CANCER INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^f WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PAMIDRONIC ACID; PLACEBO;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORBIDITY; PELVIS CANCER; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SPINE METASTASIS; THORAX CANCER; TUMOR LOCALIZATION;

ADULT; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; NEOPLASM METASTASIS;

EID: 70349849359     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-272     Document Type: Article

References (24)

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176. 10.1053/ctrv.2000.0210, 11417967.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
3. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12(20 pt 2):6243s-6249s. 10.1158/1078-0432.CCR-06-0931, 17062708.
4. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998, 16:593-602.
5. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88:1082-1090. 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z, 10699899.
6. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004, 100:2613-2621. 10.1002/cncr.20308, 15197804.
7. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
8. Kaminski M, Rosen LS, Gordon D, Zheng M, Hei Y-M. Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications. Poster presented at: Primary Therapy of Early Breast Cancer 9th International Conference; 26-29 January 2005; St. Gallen, Switzerland Abstract 107.
9. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004, 42:164-175. 10.1097/01.mlr.0000108746.69256.45, 14734954.
10. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110:1860-1867. 10.1002/cncr.22991, 17763372.
11. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69.
12. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003, 89:2031-2037. 10.1038/sj.bjc.6601437, 14647134.
13. Shirina N, Coleman RE, Chen YM. Effect of the number of bone lesions on efficacy of zoledronic acid for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors [Abstract]. J Clin Oncol 2006, 24:475s. Abstract 8529.
14. Costa L, Chen Y-M, Shirina N. Breast cancer patients without pain are at risk for skeletal-related events (SREs) and may have better outcomes with zoledronic acid compared with pamidronate. Poster presented at: 31st European Society of Medical Oncology (ESMO) Congress; 29 September-3 October 2006; Istanbul, Turkey Abstract 178P.
15. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996, 335:1785-1791. 10.1056/NEJM199612123352401, 8965890.
16. Cook RJ, Major P. Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 2001, 93:534-538. 10.1093/jnci/93.7.534, 11287447.
17. Cook RJ, Lawless JF. Marginal analysis of recurrent events and a terminating event. Stat Med 1997, 16:911-924. 10.1002/(SICI)1097-0258(19970430)16:8<911::AID-SIM544>3.0.CO;2-I, 9160488.
18. Cook RJ, Lawless JF. The Statistical Analysis of Recurrent Events. 2007, New York: Springer Science-Business Media, LLC.
19. Major PP, Cook RJ, Chen B-L, Zheng M. Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Support Cancer Ther 2005, 2:234-240. 10.3816/SCT.2005.n.017, 18628179.
20. Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002, 25(suppl 1):S10-S18. 10.1097/00000421-200212001-00003, 12562046.
21. Costa L. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast 2007, 16(suppl 3):S16-S20. 10.1016/j.breast.2007.10.005, 18032044.
22. Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004, 6:170-174. 10.3816/CLC.2004.n.030, 15555218.
23. Zheng M, Rosen L, Gordon D, Kaminski M, Howell A, Belch A, Apffelstaedt J, Hussein M, Hei YJ, Coleman R. Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases. Poster presented at: Primary Therapy of Early Breast Cancer 9th International Conference; 26-29 January 2005; St. Gallen, Switzerland. Poster 104
24. Coleman RE, Major P, Lipton A, Brown JE, Lee K-A, Smith M, Saad F, Zheng M, Hei YJ, Seaman J. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:4925-4935. 10.1200/JCO.2005.06.091, 15983391.